This week, read about shorter treatment duration for community-acquired pneumonia, how integrating hepatitis C EMR prompts and innovative community outreach are increasing patients getting tested and treated, and how professional medical organizations are leading the fight for vaccines.
Robert Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases (NFID), discusses the need to be transparent and publish the latest vaccine data, and offers clinical insights around their safety and efficacy.
Pruthvi Patel, MD, MPH, discusses how she is integrating hepatitis C EMR prompts at her institution as well as their innovative community outreach with educators to get more people into the care continuum.
New real-world data from the CIRCE study underscore cefiderocol’s potential in treating metallo-beta-lactamase–producing Enterobacterales infections, particularly among critically ill and immunocompromised patients with limited therapeutic options. Christine Slover, PharmD, offers some insights around the study and these infections.
In the second episode with Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, he discusses the federal government's attempts to suppress studies on vaccine data and how it continues the ongoing antivaccine ideology with further mis- and disinformation.
Gilead Sciences will receive FDA review for its investigational bictegravir/lenacapavir (BIC/LEN) single-tablet HIV regimen, with a decision expected by late summer.
Robert H. Hopkins Jr, MD, medical director of the National Foundation for Infectious Diseases, offers commentary about what changing the vaccine committee’s charter means from a functional standpoint and how it affects public health by moving away from vaccines as a prevention strategy.
Jason M. Goldman, MD, MACP, immediate past president of the American College of Physicians, offers insights on what the changing Advisory Committee on Immunization Practices charter means and legal steps the college is taking to prevent the federal government’s attempt to reshape the group and vaccine policy in the US.
Real-world data suggest that 3 to 4 days of antibiotics can be as effective as 5 or more days in treating community-acquired pneumonia in hospitalized patients.
A study assessing the local transmission found it caused 14 confirmed cases in 2024 and exposed diagnostic delays in patients without travel history.
This week, read a clinician's insights on a new FDA-approved HIV therapy, the CDC cancels publication of a COVID-19 vaccine study, moving up hepatitis C cure timelines, and more.
Doravirine/islatravir (Idvynso), is a non-INSTI, tenofovir-free alternative for virologically suppressed adults, with efficacy, safety, and potential benefits for aging populations managing complex treatment needs. Amy Colson, MD, MPH, offers some insights about the phase 3 trial and how clinicians may want to consider its use for patients.
Jonathan Batchelder, PhD, provides insights around his research that showed that Staphylococcus aureus can survive fluoroquinolone treatment under nutrient-limited conditions even without key DNA repair proteins, pointing to alternative survival pathways and implications for future therapies.
Emerging evidence suggests that confirming hepatitis C cure at 4 weeks post-treatment could improve patient engagement and reduce barriers to care without compromising accuracy. Meghan D. Morris, PhD, MPH, offers insights around her study on this subject.
The agency’s acting director took the unusual step of withholding the publication of the study findings in the Morbidity and Mortality Weekly Report, which showed the vaccine was protective against hospitalization and emergency department visits.
Results from a large population-based study found that receiving influenza and pertussis vaccines on the same day during pregnancy does not increase the risk of adverse maternal, birth, or neonatal outcomes compared with pertussis vaccination alone.
The federal agency has given the nod to doravirine/islatravir (Idvynso), a once-daily, 2-drug HIV treatment that demonstrated noninferior efficacy to standard 3-drug regimens in phase 3 trials, expanding options for adults with virological suppression.
Our short survey underscores the critical role of audience feedback in shaping more relevant, impactful infectious disease coverage.
In the third part of our conversation with the Peggy Lillis Foundation’s CEO Christian Lillis, he says insurance restrictions are forcing people with C diff to endure inferior treatments and repeated infections raising both human suffering and long-term healthcare costs.
A major international study reveals that World Health Organization-recommended first-line antibiotics are effective in only one in four neonatal sepsis infections in low- and middle-income countries, underscoring the growing threat of antimicrobial resistance.
AMR Action Fund CEO Henry Skinner, PhD, MBE, provides insights around the legislation including its implementation challenges which may be slowing its path to passage despite bipartisan support in Congress as well as growing recognition of the global antimicrobial resistance crisis.
New research shows that antiretroviral therapy can reduce HIV-related accelerated biological aging by nearly 4 years, highlighting the critical importance of early and sustained treatment.
This week, read about AI and antibiotic development, an innovative hepatitis C program to get postpartum mothers tested and treated sooner, on World Liver Day a nurse talks about her personal story and how she advocate for better education around this vital organ, and more.
A large real-world study from the UK Health Security Agency presented at ESCMID Global 2026 finds that maternal RSV vaccination given at least two weeks before birth cuts infant hospitalizations by more than 80%.
The latest CDC numbers show only a 0.40% increase of measles cases from week-to-week. This continues a downward trend in the percentage of cases from last week where there was only a 2.57% increase.
In honor of World Liver Day 2026, a nurse shares the heartbreaking story of her son’s fatal liver disease and her lifelong mission to educate the public about the vital, often overlooked role of liver health.
Lily Li, MD, PhD, MBA, discusses factors for increasing incidence rates including low awareness, asymptomatic spread, and gaps in testing and care access, and strategies to increase early. She also provides a brief overview for some of the testing options for the infectious disease.
In the final episode of the short series, Akhila Kosaraju, MD, talks about changing the development paradigm and moving away from reengineering molecules of existing antibiotic classes and towards creating new ones.
Madeline McCrary, MD, explains her institution’s program as a novel way to get new mothers diagnosed and given their full-course of treatment when they are still in the hospital.
Study ascertains vaccination status of children hospitalized for Bordetella pertussis infections and assesses diagnostic value of testing modalities.
